Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation

Phase 1

Completed

Conditions: Japanese Healthy Adult Male Participants

Interventions: Drug: TAK-536

First Posted Date: 2017-02-03

Last Posted Date: 2018-11-14

Lead Sponsor: Takeda

Target Recruit Count: 14

Registration Number: NCT03042299

Locations: 🇯🇵
Nishi Kumamoto Hospital, Kumamoto, Japan

Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus

Phase 4

Withdrawn

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Alogliptin

First Posted Date: 2017-02-03

Last Posted Date: 2017-10-20

Lead Sponsor: Takeda

Registration Number: NCT03042325

Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults

Phase 2

Completed

Conditions: Norovirus
Healthy Volunteers

Interventions: Biological: NoV Vaccine

First Posted Date: 2017-02-01

Last Posted Date: 2022-11-09

Lead Sponsor: Takeda

Target Recruit Count: 528

Registration Number: NCT03039790

Locations: 🇺🇸
Simon-Williamson Clinic/Synexus Clinical Research US, Inc, Birmingham, Alabama, United States
🇺🇸
Synexus Clinical Research US, Inc/Southwest Family Medicine, Littleton, Colorado, United States
🇺🇸
Miami Research Associates, Miami, Florida, United States

and more 8 locations

Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease

Phase 3

Withdrawn

Conditions: Primary Sclerosing Cholangitis
Inflammatory Bowel Disease

Interventions: Drug: Vedolizumab
Drug: Placebo

First Posted Date: 2017-01-27

Last Posted Date: 2017-03-08

Lead Sponsor: Takeda

Registration Number: NCT03035058

Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis

Phase 4

Completed

Conditions: Colitis, Ulcerative

Interventions: Drug: Vedolizumab IV

First Posted Date: 2017-01-24

Last Posted Date: 2023-07-28

Lead Sponsor: Takeda

Target Recruit Count: 278

Registration Number: NCT03029143

Locations: 🇺🇸
University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
🇺🇸
Atlanta Center for Gastroenterology, Decatur, Georgia, United States
🇺🇸
Gastroenterology Associates of Northern Virginia, Ltd., Fairfax, Virginia, United States

and more 45 locations

Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus

Phase 4

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Daily DPP-4 inhibitor
Drug: Trelagliptin

First Posted Date: 2017-01-09

Last Posted Date: 2023-12-22

Lead Sponsor: Takeda

Target Recruit Count: 219

Registration Number: NCT03014479

Locations: 🇯🇵
Takeda Selected Site 1, Suita, Osaka, Japan
🇯🇵
Takeda Selected Site 13, Shinagawa-ku, Tokyo, Japan
🇯🇵
Takeda Selected Site 8, Shinjuku-ku, Tokyo, Japan

and more 24 locations

A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants

Completed

Conditions: Central Precocious Puberty

Interventions: Drug: GnRH agonist
Drug: Enantone

First Posted Date: 2016-12-15

Last Posted Date: 2022-03-16

Lead Sponsor: Takeda

Target Recruit Count: 108

Registration Number: NCT02993926

Locations: 🇨🇳
The Children's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳
Childrens Hospital of Hunan province, Changsha, Hunan, China
🇨🇳
Jiangsu Province Hosptial, Nanjing, Jiangsu, China

and more 2 locations

Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Alogliptin
Drug: Alogliptin FDC With Pioglitazone
Drug: Alogliptin FDC With Metformin

First Posted Date: 2016-12-12

Last Posted Date: 2019-04-19

Lead Sponsor: Takeda

Target Recruit Count: 593

Registration Number: NCT02989649

A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive Participants With Ulcerative Colitis (UC) or Crohn´s Disease (CD)

Completed

Conditions: Crohn Disease
Colitis, Ulcerative
Inflammatory Bowel Diseases

First Posted Date: 2016-12-08

Last Posted Date: 2020-09-25

Lead Sponsor: Takeda

Target Recruit Count: 60

Registration Number: NCT02986724

A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Hodgkin Disease

Interventions: Drug: Brentuximab vedotin
Drug: Doxorubicin
Drug: Vinblastine
Drug: Dacarbazine

First Posted Date: 2016-12-01

Last Posted Date: 2024-02-20

Lead Sponsor: Takeda

Target Recruit Count: 59

Registration Number: NCT02979522

Locations: 🇧🇷
ICr - Instituto da Crianca - HCFMUSP, Sao Paulo, Brazil
🇮🇹
Ospedale Pediatrico Bambino Gesu,UOC Onco-ematologia, Roma, Italy
🇧🇷
Hospital Santa Marcelina, Sao Paulo, Brazil

and more 11 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy